Insider Trading Alert - SKT, HEB And NURO Traded By Insiders

Yesterday, Aug. 20, 2015, 99 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $10,960,360.00.

Highlighted Stocks Traded by Insiders:

Tanger Factory Outlet Centers (SKT) - FREE Research Report

Geldner Carrie A, who is SVP, Chief Marketing Officer at Tanger Factory Outlet Centers, sold 1,200 shares at $33.47 on Aug. 20, 2015. Following this transaction, the SVP, Chief Marketing Officer owned 51,848 shares meaning that the stake was reduced by 2.26% with the 1,200-share transaction.

The shares most recently traded at $33.01, down $0.46, or 1.41% since the insider transaction. Historical insider transactions for Tanger Factory Outlet Centers go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 5,032
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 15,032
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 131,512

The average volume for Tanger Factory Outlet Centers has been 650,200 shares per day over the past 30 days. Tanger Factory Outlet Centers has a market cap of $3.2 billion and is part of the financial sector and real estate industry. Shares are down 10.58% year-to-date as of the close of trading on Thursday.

Tanger Factory Outlet Centers, Inc. is a real estate investment trust. The firm invests in the real estate markets in United States. It focuses on developing, acquiring, owning, operating, and managing outlet shopping centers. Tanger Factory Outlet Centers, Inc. The stock currently has a dividend yield of 3.41%. The company has a P/E ratio of 32.2. Currently, there are no analysts who rate Tanger Factory Outlet Centers a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKT - FREE

TheStreet Quant Ratings rates Tanger Factory Outlet Centers as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Tanger Factory Outlet Centers Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hemispherx Biopharma (HEB) - FREE Research Report

Carter William A, who is Ceo at Hemispherx Biopharma, bought 25,000 shares at $0.18 on Aug. 20, 2015. Following this transaction, the Ceo owned 1.2 million shares meaning that the stake was boosted by 2.08% with the 25,000-share transaction.

The shares most recently traded at $0.17, down $0.01, or 5.59% since the insider transaction. Historical insider transactions for Hemispherx Biopharma go as follows:

  • 4-Week # shares bought: 129,104
  • 12-Week # shares bought: 129,104
  • 24-Week # shares bought: 729,104

The average volume for Hemispherx Biopharma has been 819,400 shares per day over the past 30 days. Hemispherx Biopharma has a market cap of $44.4 million and is part of the health care sector and drugs industry. Shares are down 30.08% year-to-date as of the close of trading on Thursday.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. Currently, there are no analysts who rate Hemispherx Biopharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HEB - FREE

TheStreet Quant Ratings rates Hemispherx Biopharma as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Hemispherx Biopharma Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NeuroMetrix (NURO) - FREE Research Report

Higgins Thomas T, who is Senior Vice President, CFO at NeuroMetrix, bought 5,500 shares at $0.91 on Aug. 20, 2015. Following this transaction, the Senior Vice President, CFO owned 80,994 shares meaning that the stake was boosted by 7.29% with the 5,500-share transaction.

The shares most recently traded at $0.92, up $0.01, or 1.2% since the insider transaction. Historical insider transactions for NeuroMetrix go as follows:

  • 4-Week # shares bought: 34,157
  • 12-Week # shares bought: 34,157
  • 24-Week # shares bought: 34,157

The average volume for NeuroMetrix has been 301,700 shares per day over the past 30 days. NeuroMetrix has a market cap of $10.0 million and is part of the health care sector and health services industry. Shares are down 51.28% year-to-date as of the close of trading on Thursday.

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis, and diabetes. Currently, there is 1 analyst who rates NeuroMetrix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NURO - FREE

TheStreet Quant Ratings rates NeuroMetrix as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full NeuroMetrix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow, S&P 500 Set Record Highs as Wall Street Looks Past Trade Fears

Dow, S&P 500 Set Record Highs as Wall Street Looks Past Trade Fears

Goldman Names Dees Co-Head of Investment Banking

Goldman Names Dees Co-Head of Investment Banking

'Millennials Have a Strong Voice' Says Deloitte CEO: LIVE BLOG

'Millennials Have a Strong Voice' Says Deloitte CEO: LIVE BLOG

How Violent Will the Tilray Stock Crash Be?

How Violent Will the Tilray Stock Crash Be?

GE Shares Slide as JPMorgan Lowers Price Target on Gas Turbine Concerns

GE Shares Slide as JPMorgan Lowers Price Target on Gas Turbine Concerns